Lilly is ramping up future manufacturing for Foundayo obesity pill

Key Points:

• Eli Lilly's CEO Dave Ricks revealed that one-third of new GLP-1 pill patients are using the company's Foundayo, with market share growing weekly as Lilly aims to catch up to rival Novo.
• Lilly broke ground on a $6.5 billion manufacturing facility in Houston, Texas, set to be operational by 2030, which will produce Foundayo and active ingredients for other small-molecule medicines across various disease areas.
• Despite Novo being first to market with a GLP-1 pill, Lilly held about a 61% share of the overall obesity and diabetes pill market in Q2, highlighting strong demand and competitive positioning.
• Lilly has invested over $50 billion since 2020 in expanding its U.S. manufacturing network, including a recent $27 billion commitment for four new facilities, emphasizing manufacturing capacity as a key competitive advantage.
• The demand for Foundayo is increasing, with $98 million in sales during its first full quarter, boosted by new Medicare coverage for obesity drugs starting in July, which also benefits Lilly’s weight loss drug Zepbound.